Literature DB >> 22740883

High mobility group B1 protein interacts with its receptor RAGE in tumor cells but not in normal tissues.

Jordana Todorova1, Evdokia Pasheva.   

Abstract

The high mobility group box 1 (HMGB1) protein is an abundant non-histone component of chromatin well known for its two DNA binding domains, HMG box A and HMG box B. The main characteristics of the HMGB1 protein as an 'architectural' factor are its ability to recognize and bind with high affinity to distorted DNA and its ability to induce kinks in linear DNA fragments. The HMGB1 protein has been correlated to cancer progression. An elevated expression of HMGB1 occurred in certain types of primary tumor, including melanoma and colon, prostate, pancreatic and breast cancers, and in the majority of cases HMGB1 is associated with invasion and metastasis. The main signaling pathway is activated through the interaction of HMGB1 with its Receptor for Advanced Glycation End products (RAGE). Certain data indicate that an elevated expression of RAGE and HMGB1 is not always a prerequisite of poor prognosis of tumor development. The cellular localization of the ligand/receptor pair also requires consideration. The data concerning the expression of HMGB1 protein and its receptor RAGE in various tissues and tumor cells reflect the overall production of the proteins. However, they do not refer to their cellular localization and there is no direct evidence for the formation of a stable complex between them. In the present study, we investigated the subcellular distribution of HMGB1 and its receptor RAGE in various rat organs compared to Guerin ascites tumor cells. In the normal tissues the proteins exist in their soluble form, whereas in the tumor cells they are insoluble and membrane-bound. HMGB1 forms a stable complex with RAGE only in the protein extract derived from the cancer cells predominantly in the membrane fraction.

Entities:  

Year:  2011        PMID: 22740883      PMCID: PMC3362388          DOI: 10.3892/ol.2011.459

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  35 in total

1.  Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases.

Authors:  A Taguchi; D C Blood; G del Toro; A Canet; D C Lee; W Qu; N Tanji; Y Lu; E Lalla; C Fu; M A Hofmann; T Kislinger; M Ingram; A Lu; H Tanaka; O Hori; S Ogawa; D M Stern; A M Schmidt
Journal:  Nature       Date:  2000-05-18       Impact factor: 49.962

2.  Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion.

Authors:  Tiziana Bonaldi; Fabio Talamo; Paola Scaffidi; Denise Ferrera; Annalisa Porto; Angela Bachi; Anna Rubartelli; Alessandra Agresti; Marco E Bianchi
Journal:  EMBO J       Date:  2003-10-15       Impact factor: 11.598

3.  The DNA chaperone HMGB1 facilitates ACF/CHRAC-dependent nucleosome sliding.

Authors:  Tiziana Bonaldi; Gernot Längst; Ralf Strohner; Peter B Becker; Marco E Bianchi
Journal:  EMBO J       Date:  2002-12-16       Impact factor: 11.598

4.  Occurrence of amphoterin (HMG1) as an endogenous protein of human platelets that is exported to the cell surface upon platelet activation.

Authors:  A Rouhiainen; S Imai; H Rauvala; J Parkkinen
Journal:  Thromb Haemost       Date:  2000-12       Impact factor: 5.249

5.  Specific recognition of cruciform DNA by nuclear protein HMG1.

Authors:  M E Bianchi; M Beltrame; G Paonessa
Journal:  Science       Date:  1989-02-24       Impact factor: 47.728

6.  Specific binding of chromosomal protein HMG1 to DNA damaged by the anticancer drug cisplatin.

Authors:  P M Pil; S J Lippard
Journal:  Science       Date:  1992-04-10       Impact factor: 47.728

7.  Secretion and binding of HMG1 protein to the external surface of the membrane are required for murine erythroleukemia cell differentiation.

Authors:  M Passalacqua; A Zicca; B Sparatore; M Patrone; E Melloni; S Pontremoli
Journal:  FEBS Lett       Date:  1997-01-06       Impact factor: 4.124

Review 8.  Masquerader: high mobility group box-1 and cancer.

Authors:  Jessica E Ellerman; Charles K Brown; Michael de Vera; Herbert J Zeh; Timothy Billiar; Anna Rubartelli; Michael T Lotze
Journal:  Clin Cancer Res       Date:  2007-05-15       Impact factor: 12.531

Review 9.  RAGE (Receptor for Advanced Glycation Endproducts), RAGE ligands, and their role in cancer and inflammation.

Authors:  Louis J Sparvero; Denise Asafu-Adjei; Rui Kang; Daolin Tang; Neilay Amin; Jaehyun Im; Ronnye Rutledge; Brenda Lin; Andrew A Amoscato; Herbert J Zeh; Michael T Lotze
Journal:  J Transl Med       Date:  2009-03-17       Impact factor: 5.531

10.  High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes.

Authors:  U Andersson; H Wang; K Palmblad; A C Aveberger; O Bloom; H Erlandsson-Harris; A Janson; R Kokkola; M Zhang; H Yang; K J Tracey
Journal:  J Exp Med       Date:  2000-08-21       Impact factor: 14.307

View more
  22 in total

1.  Correlation of HMGB1 expression to progression and poor prognosis of adenocarcinoma and squamous cell/adenosquamous carcinoma of gallbladder.

Authors:  Zilu Shi; Qian Huang; Jian Chen; Pengcheng Yu; Xiaosong Wang; Hong Qiu; Yijie Chen; Yangyang Dong
Journal:  Am J Transl Res       Date:  2015-10-15       Impact factor: 4.060

Review 2.  Role of high-mobility group box 1 protein in inflammatory bowel disease.

Authors:  Zhen Hu; Xiaoyun Wang; Lei Gong; Gaojue Wu; Xiaobin Peng; Xuejun Tang
Journal:  Inflamm Res       Date:  2015-06-16       Impact factor: 4.575

Review 3.  HMGB1 in hormone-related cancer: a potential therapeutic target.

Authors:  Madhuwanti Srinivasan; Souresh Banerjee; Allison Palmer; Guoxing Zheng; Aoshuang Chen; Maarten C Bosland; André Kajdacsy-Balla; Ramaswamy Kalyanasundaram; Gnanasekar Munirathinam
Journal:  Horm Cancer       Date:  2014-04-10       Impact factor: 3.869

4.  High-sensitivity C-reactive protein and high mobility group box-1 levels in Parkinson's disease.

Authors:  Aslıhan Baran; Mahmut Bulut; Mehmet Cemal Kaya; Özlem Demirpençe; Bünyamin Sevim; Eşref Akıl; Sefer Varol
Journal:  Neurol Sci       Date:  2018-10-23       Impact factor: 3.307

5.  TLR4 is essential for dendritic cell activation and anti-tumor T-cell response enhancement by DAMPs released from chemically stressed cancer cells.

Authors:  Hongliang Fang; Bing Ang; Xinyun Xu; Xiaohui Huang; Yanfeng Wu; Yanping Sun; Wenying Wang; Nan Li; Xuetao Cao; Tao Wan
Journal:  Cell Mol Immunol       Date:  2013-12-23       Impact factor: 11.530

6.  Co-expression of RAGE and HMGB1 is associated with cancer progression and poor patient outcome of prostate cancer.

Authors:  Chu-Biao Zhao; Ji-Ming Bao; Yong-Jie Lu; Tong Zhao; Xin-Hua Zhou; Da-Yong Zheng; Shan-Chao Zhao
Journal:  Am J Cancer Res       Date:  2014-07-16       Impact factor: 6.166

Review 7.  Ousting RAGE in melanoma: A viable therapeutic target?

Authors:  Deeba N Syed; Ahmed Aljohani; Durdana Waseem; Hasan Mukhtar
Journal:  Semin Cancer Biol       Date:  2017-10-24       Impact factor: 15.707

8.  Controlling cancer-induced inflammation with a nucleic acid scavenger prevents lung metastasis in murine models of breast cancer.

Authors:  Eda K Holl; Victoria Frazier; Karenia Landa; David Boczkowski; Bruce Sullenger; Smita K Nair
Journal:  Mol Ther       Date:  2020-12-19       Impact factor: 11.454

9.  miR-340-5p inhibits pancreatic acinar cell inflammation and apoptosis via targeted inhibition of HMGB1.

Authors:  Yazhou Gao; Liming Wang; Zequn Niu; Hui Feng; Jie Liu; Jiangli Sun; Yanxia Gao; Longfei Pan
Journal:  Exp Ther Med       Date:  2021-12-14       Impact factor: 2.447

10.  Overexpression of high mobility group box 1 and 2 is associated with the progression and angiogenesis of human bladder carcinoma.

Authors:  Wei Wang; Haowen Jiang; Hechen Zhu; Hu Zhang; Jian Gong; Limin Zhang; Qiang Ding
Journal:  Oncol Lett       Date:  2012-12-27       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.